Fallopian Tube Carcinoma

J Oncol Pract. 2019 Jul;15(7):375-382. doi: 10.1200/JOP.18.00662. Epub 2019 Jul 8.

Abstract

Primary fallopian tube carcinoma is a rare and difficult to cure disease. It is often grouped under the epithelial ovarian cancer umbrella, together with primary ovarian and peritoneal carcinomas. More recent evidence has suggested that epithelial ovarian cancers originate from a fallopian tube precursor. The mainstay of treatment is surgical cytoreduction and platinum-based chemotherapy. There is much debate over the best timing for surgery and the best approach to delivering the chemotherapy: traditional intravenous once every 3 weeks regimen, versus intraperitoneal, versus dose-dense intravenous regimens. Although these debates continue, novel targeted therapies, including bevacizumab and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors, have emerged. PARP inhibitors are particularly efficacious in patients with BRCA1/2 gene mutations, and their use has been shown to prolong patient survival. This article reviews the pathologic etiology; describes the heredity, treatment challenges, and controversies; and summarizes novel therapies in primary fallopian tube carcinoma.

Publication types

  • Review

MeSH terms

  • Carcinoma in Situ / epidemiology
  • Carcinoma in Situ / genetics
  • Carcinoma in Situ / therapy
  • Fallopian Tube Neoplasms* / epidemiology
  • Fallopian Tube Neoplasms* / genetics
  • Fallopian Tube Neoplasms* / therapy
  • Female
  • Humans
  • Incidence